Leading quality in injectables
Corporate Profile WWW.DEMO.GR
CONTENTS 04. Introduction
06. Corporate Philoshophy
08. Global Presence
10. Our Facilities
12. Business Segments
14. Quality Assurance
16. Investing in our People
18. Investing in Innovation
20. Corporate Responsibility
22. PRODUCTION CAPABILITIES
2
DEMO S.A.
CHAIRMAN WORD
F
ifty years ago we pledged to develop and expand with only one purpose: to provide the best selection of products in the pharmaceutical sector. Our vision and strategy focused on the production of high quality pharmaceutical products with competitive prices, the marketing of innovative products for the relief of chronic disease and international export activities.i
STAVROS DEMOS PRESIDENT
DEMO SA
3
our COMPANY 50 years of dynamic presence in Greece and Wordwide
DEMO S.A. Pharmaceutical Industry is an industrial and commercial organization established in 1965 and active in the production and sales of pharmaceutical products. We are one of the major pharmaceutical manufacturers in Greece with a very strong presence in the hospital market, ranking first among the pharmaceutical companies in terms of sold units. With an annual turnover of 123.500.000 € in 2015, and average annual growth rates of 8% over the past 10 years we rank as one of the top pharmaceutical companies in the region. Our product portfolio includes many injectable generic pharmaceutical formulations from several therapeutic categories including: • • • • • •
Carbapenem sterile powders Cephalosporin sterile powders Freeze-dried formulations Blow-fill-sealed ampoules and bottles Parenteral electrolyte solutions Oral forms
Currently present in more than 50 countries worldwide, including countries in Europe, Asia, Africa, Latin America, Oceania & the Middle East. Our cutting edge production facilities allow us to offer our partners services such as: • • •
Worldwide distribution opportunities Out-licensing support Contract manufacturing operations.
Greek medicines with a global reach 4
DEMO S.A.
milestones in history 2015
2015 launch demo gmbh Pharmaceutical Germany
2013 BD office china 2011 new carbapenem facility
2010 2008 4th manufacturing plant salonica 2006 3rd manufacturing plant
2005 2004 state of-the-art quality control & r&d lab 2000 2nd manufacturing plant 1997 first plastic ambule production line
1996 stategic shift to hospital market
1995
1985 international sales division
1985
1975 1974 sales manufacturing plant
1965 1965 Establishment of DEMO DEMO SA
5
corporate phyloshophy DEMO commitment to top quality.
vision Our vision is to provide quality, as well as reliable and innovative pharmaceutical products worldwide. Our goal is to be consistently one of the best companies in the pharmaceutical market, maintaining our leadership position in the Greek industry, the positive growth rate and the preference of our customers and partners that is based on their confidence for the products we produce
MIsion DEMO intends to remain on top of the Greek pharmaceutical industry while further establish its position as one of the leading manufacturing companies worldwide. Having already achieved rapid growth in the global generics pharmaceutical market, we aim to contribute with innovative, quality products and services, improving the lives of patients worldwide and ensuring the steady confidence of our customers. Our modern and fully equipped manufacturing premises, the advanced technologies that we have adopted, our constant product portfolio expansion and our international presence are the means to the end. Therefore, we have invested heavily in the creation and sourcing of our state-of-theart Research & Development laboratory. DEMO’s R&D lab spans more than, 1.500 m2 is equipped with the latest instruments and is staffed with the top graduates of the University of Athens. Under the supervision of highly qualified researchers – most of who own PhD degrees from the most acclaimed universities in Europe – our R&D lab represents the company’s launching pad for the future
6
DEMO S.A.
our values Since the founding of our company, the quality of our products has consistently been our top priority. Throughout the company’s history, we have heavily invested in the modernization and improvement of our production premises as well as our Quality Control department
DEMO SA
7
Global presence
Export’s Champions Established in 1985, the company’s International Sales Division has seen dramatic increase in its annual turnover and is a major contributor to the company’s growth. In 2004, DEMO ranked as the top exporter of pharmaceutical products in Greece and has held that position since. Currently present in 52 countries – including countries in Europe, Asia, Africa, Oceania & South America – we have 900 registered products globally and are continuously expanding our brand worldwide. With a compound annual growth of more than 29% during the last years, the company’s International Sales Division is projected to contribute at least 30%-35% to the firm’s revenue within the next years. During 2007, our International 8
DEMO S.A.
Sales Division completed a major restructuring project to enable it to drive the company’s growth during the next 5 to 10 years. DEMO is actively monitoring worldwide markets to identify those products that become off-patent and are of great importance to the global healthcare community. We are committed to the development of 8 to 10 new blockbuster products every year, laying the company’s foundation for the future. At the same time, research projects are often undertaken in association with the University of Athens that will enable the company to enter new markets..
Internationally recognized Officially Approved Supplier of the • • • •
United Nations, UNICEF, World Health Organization (WHO), MSF
Approved by the Korean-FDA Approved by Brazilian Drug Agency (ANVISA) Approved by GCC (Health Minister’s Council for Cooperation Council States) – Gulf countries Many other health authorities of non-EU countries (Jordan, South Africa MCC, Egypt, Turkey, etc.) DEMO SA
9
our facilities
athens / greece MAIN PREMISES
21st km Nat. Road Athens-Lamia,145 68 Krioneri Attica, Greece Τel: +30 210 8161802 Fax: +30 210 8161587
salonica / greece SUPPORT PREMISES
15th km Salonica-N. Moudania Road, 570 01 Thermi, Salonica, Greece, Τel: +30 231 0 31 75 67
hallbergmoos / Germany OFFICE
Am Söldnermoos 17 (ABC), D-85399, Hallbergmoos, Germany
sanghai / people’s Republic of china OFFICE
2/F 08-A29 Zhongshan, West Road Xuhui District, Shanghai, People’s Republic of China
10 DEMO S.A.
the largest pharmaceutical factory of southeastern europe Our headquarters are located in the industrial zone of Athens and specifically in the northern suburbs. With branch offices in the biggest cities of Greece, we are able to supply our customers anywhere in the countrywithin less than 48 hours. Our three manufacturing facilities spanning 45,000 m2 are located in the company’s campus
This fact, along with high tech warehousing facilities in both Athens and Salonika provide our company with the unique ability to offer our own logistic services to all hospitals countrywide.
45.000m2 FACILITIES
4
MANYFACTURING SUB-UNITS
21
PRODUCTION LINES DEMO SA 11
Business segments DOMESTIC SALES & MARKETING Our company’s Sales and Marketing Departments employ well trained and highly specialized staff. We have a daily presence in all hospital institutions of the country, both public (hospitals) and private (hospitals and clinics).
RENAL Our company started producing its first renal products in 1996 via a complete range of hemodialysis solutions. In parallel, it supplies the Greek market with dialysers, catheters, blood lines and dialysis machines.
HEMATOLOGY PRIVATE MARKET We provide the Private Market with cardiology, pulmonology, pathology, general medicine, neurology, and urology products.
Our Hematology Department (H.B.U.) promotes pharmaceutical products unique in their category, for example for the treatment of rare hemoglobinopathies, such as thalassemia and sickle cell disease: Ferriprox (deferiprone), Siklos (hydroxycarbamide)
GENERAL HOSPITALPRODUCTS Our company currently provides hospital institutions with unique and irreplaceable products, such as Adrenaline and other products assigned directly from EOF. We also offer a wide range of saline solutions and ampoules.
HOSPITAL ANTIBIOTICS We offer a complete range of antibiotic products for the efficient treatment of infections in hospitals.
oncology Our Oncology Department promotes two products in the category of biosimilars. Binocrit (epoetin-A) and Zarzio (filgrastim). Both come from the multinational company Novartis. In the near future, our oncology portfolio will be enhanced with new products.
12 DEMO S.A.
LEADING THE GREEK MARKET
DEMO SA 13
Research & development Investing in innovation During the past 50 years, our product portfolio has grown significantly providing the foundation for the company’s success. To sustain this in the future, the Board of Directors has committed to develop 8 to 10 new products per year and launch them in the global market as soon as they go off-patent. Furthermore, a number of new research projects are under progress that will allow DEMO to become an innovative group of companies in the international pharmaceutical market. For this reason, we have invested heavily in the creation and sourcing of our modern and high tech Research & Development laboratory. DEMO’s R&D lab spans more than 1,500m2, is equipped with the latest instruments and is staffed with the top graduates of the University of Athens. Under the supervision of highly qualified researchers – most of who own PhD degrees from the most acclaimed universities in Europe – our R&D lab represents the company’s launching pad for the following decades.
Dedicated Department of Regulatory Affairs In order for our company to be successful in its international endeavors it was clear that we needed to build in-house expertise which would allow us to provide regulatory support to our partners worldwide. Hence, in 2005 we established an independent Regulatory Affairs Department staffed with 15 full time regulatory officers charged with preparing files for submission and approval to the appropriate regulatory authorities worldwide. Our products’ registration files are all in CTD (Common Technical Document) format, which allows us to quickly and efficiently proceed with submissions in multiple countries simultaneously. Furthermore, our participation in national, mutual (MRP) and decentralized (DCP) registration processes worldwide have deemed our regulatory affairs department as one of the most competent, providing invaluable support to our partners globally. Last but not least, we have dedicated regulatory officers that constantly monitor local & regional regulatory conditions, providing immediate response in case there are any changes in local requirements.
14 DEMO S.A.
Quality is our priority.
Committed to Top Quality Since the company’s establishment, the quality of our products has consistently been our top concern. For this reason, throughout the company’s history, we have heavily invested in the modernization and improvement of our production premises as well as our Quality Control Department. As a result, all of our manufacturing premises use highly automated manufacturing procedures and are equipped with state-of-the-art technology certifications: – cGMP certified (current Good Manufacturing Practices) – ISO 9001 Moreover, our new Quality Control Laboratory conforms to the latest Good Laboratory Procedures and exceeds 1,500 m2. It has been rated as one of the best in Europe and is fully equipped with state-of-the-art devices. Furthermore, our long-time cooperation with both the Chemistry and Biology Departments of the University of Athens provides us with an unlimited pool of talent to draw from in order to staff our laboratories with best-in-class scientists.
DEMO SA 15
investing in our people
Natque et aut mi, volentes ma quam nust mi, quis erum volorecto eat.To quisint minto dolupta tiatias simaxim pellauta quaestrumAximi, utemole stoNamus aut audaepu dicat.To inusand itiberchit ulparch itatis a qui nulpa delAm eosam con nis nation pore es eles molorest mos eostio es est, que alisque sum ene doles sam explique cusRibeaquis alique apedit, nis aut quae la di commoluptam ut es volorrum quidus, Quat omnimodi dis estior alicia ipitiaerrum fugiamet harchic tem cor saperum et et atur? Natque et aut mi, volentes ma quam nust mi, quis erum volorecto eat.To quisint minto dolupta tiatias simaxim pellauta quaestrumAximi, utemole stoNamus aut audaepu dicat.To inusand itiberchit ulparch itatis a qui nulpa delAm eosam con nis nation pore es eles molorest mos eostio es est, que alisque sum ene doles sam explique cusRibeaquis alique apedit, nis aut quae la di commoluptam ut es volorrum quidus, Quat omnimodi dis estior alicia ipitiaerrum fugiamet harchic tem cor saperum et et atur? Natque et aut mi, volentes ma quam nust mi, quis erum volorecto eat.To quisint minto dolupta tiatias simaxim pellauta quaestrumAximi, utemole stoNamus aut audaepu dicat.To inusand itiberchit ulparch itatis a qui nulpa delAm eosam con nis nation pore es eles molorest mos eostio es est, que alisque sum ene doles sam explique cusRibeaquis alique apedit, nis aut quae la di commoluptam ut es volorrum quidus, Quat omnimodi dis estior alicia ipitiaerrum fugiamet harchic tem cor saperum et et atur? Natque et aut mi, volentes ma quam nust mi, quis erum volorecto eat.To quisint minto dolupta tiatias simaxim pellauta quaestrumAximi, utemole stoNamus aut audaepu dicat.To inusand itiberchit ulparch itatis a qui nulpa delAm eosam con nis nation pore es eles molorest mos eostio es est, que alisque sum ene doles sam explique cusRibeaquis alique apedit, nis aut quae la di commoluptam ut es volorrum quidus, Quat omnimodi dis estior alicia ipitiaerrum fugiamet harchic tem cor saperum et et atur?
16 DEMO S.A.
Natque et aut mi, volentes ma quam nust mi, quis erum volorecto eat.To quisint minto dolupta tiatias simaxim pellauta quaestrumAximi, utemole stoNamus aut audaepu dicat.To inusand itiberchit ulparch itatis a qui nulpa delAm eosam con nis nation pore es eles molorest mos eostio es est, que alisque sum ene doles sam explique cusRibeaquis alique apedit, nis aut quae la di commoluptam ut es volorrum quidus, Quat omnimodi dis estior alicia ipitiaerrum fugiamet harchic tem cor saperum et et atur? Natque et aut mi, volentes ma quam nust mi, quis erum volorecto eat.To quisint minto dolupta tiatias simaxim pellauta quaestrumAximi, utemole stoNamus aut audaepu dicat.To inusand itiberchit ulparch itatis a qui nulpa delAm eosam con nis nation pore es eles molorest mos eostio es est, que alisque sum ene doles sam explique cusRibeaquis alique apedit, nis aut quae la di commoluptam ut es volorrum quidus, Quat omnimodi dis estior alicia ipitiaerrum fugiamet harchic tem cor saperum et et atur? Natque et aut mi, volentes ma quam nust mi, quis erum volorecto eat.To quisint minto dolupta tiatias simaxim pellauta quaestrumAximi, utemole stoNamus aut audaepu dicat.To inusand itiberchit ulparch itatis a qui nulpa delAm eosam con nis nation pore es eles molorest mos eostio es est, que alisque sum ene doles sam explique cusRibeaquis alique apedit, nis aut quae la di commoluptam ut es volorrum quidus, Quat omnimodi dis estior alicia ipitiaerrum fugiamet harchic tem cor saperum et et atur? Natque et aut mi, volentes ma quam nust mi, quis erum volorecto eat.To quisint minto dolupta tiatias simaxim pellauta quaestrumAximi, utemole stoNamus aut audaepu dicat.To inusand itiberchit ulparch itatis a qui nulpa delAm eosam con nis nation pore es eles molorest mos eostio es est, que alisque sum ene doles sam explique cusRibeaquis alique apedit, nis aut quae la di commoluptam ut es volorrum quidus, Quat omnimodi dis estior alicia ipitiaerrum fugiamet harchic tem cor saperum et et atur?
DEMO SA 17
corporate responsibility the importance of offering The company recycles impressive quantities of plastic and paper, realizes by its own means the gathering of the company’s solid waste and transfers it to be destroyed, whereas simultaneously it sees to it that the procedures of proper management for building facilities and registration of our carbon imprint are followed, as it ought to as a modern industry. As capping-stone of the company’s commitment for the enforcement of cultural activities and the promotion of sports and “fair play”, DEMO has contributed as a sponsor to a number of artistic and sport activities. However, for DEMO even its productive activity itself is always at the service of every human life. The company produces medicine of special compositions, for rare isolated cases that have been ordered, even for one and unique patient, after a special permit. DEMO’s possibility to stop for 8 hours a production line of 15.000 phials per hour so as to produce 20 or 30 phials that will save even one person, is to DEMO perhaps the most important act of Social Responsibility.
Environment
Employee
•
Paper Recycling 121tn// year
•
Job access
•
Plastic Recycling 954tn /year
•
Promote Voluntarism
•
Solid Waste 362 tn / year
•
DEMO Blood Bank
•
Greenhouse Gasses 2.369kg/year
•
Private Health Insurance programs
•
Saving 32.311 trees/ year
•
Talent Management
•
Saving 66.293 liters of water/year
•
Team Bonding activities
•
CSR Working Group
•
Educational Programs & Seminars
18 DEMO S.A.
Viable Growth and Responsible Entrepreneurship constitutes a commitment for DEMO Responsible Entrepreneurship and the continuous effort for Viable Growth must constitute a strategic choice for any modern enterprise, let alone for a national champion, like DEMO is. In this way its long term and progress is furthermore assured. For us, responsible entrepreneurship firstly means to daily act with ethics, having in mind, beyond the progress of our company, the general society progress. Beyond the responsibility as an ethical value, we believe that responsible enterprises are those which plan with a long term horizon, invest and stand on sound foundations. Responsible and therefore viable growth for us means creation of added value for Greek economy and society∙ through the initiatives supporting the worker, the colleague, the patient, the citizen, the environment. The axes on which we rely on are the cooperation with the local societies, innovation, exports, the decrease of the environmental fingerprint and the investment to human resources. Thus, we consider that we give back to society its trust and at the same time we create a stable basis for the healthy course of our company in the future.
ethical marketing
society
•
Member of Pharma Associations
•
•
Member of Institutions for Sustainability
•
Investments and hi taxes payment
•
Support Children’s Refuges
•
Transparency in communicating with stake-
•
Promote and Support Athletics
Social Pharmacies, etc
holders •
Act in accordance with International and Na-
Donations to Hospitals, NGO’s,
(Para Olympic Games) •
Donations in schools and local communities
tional Law •
Certified by Trace International
•
(Anti Bribery & Transparency Compliance)
DEMO SA 19
contact us ..................................... ..................................... PHONNE FAX
: + .......................... : + ..........................
EMAIL WEBSITE
: .................... : .....................